Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Regeneron (NASDAQ: REGN) today and set a price target of $385. The company’s shares opened today at $398.52.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.7% and a 48.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Regeneron with a $406.17 average price target, implying a 1.9% upside from current levels. In a report issued on October 11, Morgan Stanley also maintained a Hold rating on the stock with a $412 price target.
.
See today’s analyst top recommended stocks >>
Based on Regeneron’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $551 million. In comparison, last year the company had a net profit of $388 million.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
